13F Pro13F Pro

SEC Form 4 reporting owner

Orbimed Advisors LLC

Orbimed Advisors LLC has filed 95 Form 4 transactions reported between November 21, 2025 and November 16, 2026, as Director of WINDWARD BIO GROUP AG, Director of Electra Therapeutics, Inc., Director of Aspen Neuroscience, Inc., Director of ADARx Pharmaceuticals, Inc., Director of BlossomHill Therapeutics, Inc., Director of Braveheart Bio, Inc., Director of Scribe Therapeutics, Inc., Director of Sionna Therapeutics, Inc., 10% owner of Enliven Therapeutics, Inc., Director of Shattuck Labs, Inc., Director of Q32 Bio Inc., Director of Prelude Therapeutics Inc, 10% owner of Traws Pharma, Inc., Director of ImageneBio, Inc., 10% owner of Adicet Bio, Inc. and Director of Keros Therapeutics, Inc..

Name as filed: ORBIMED ADVISORS LLC

Follow Orbimed Advisors LLC and get an alert on every new Form 4

Orbimed Advisors LLC holds 6.6M shares of ELVN, worth $304.2M, 8.91% of the company.

As of their Jun 22, 2026 Form 4 (filed Jun 24, 2026) · the filing on SEC EDGAR · valued at the Nov 19, 2026 close of $46.41 · 73.6M shares outstanding on Oct 28, 2026

That filing was marked as no longer subject to Section 16, so later changes may not be reported.

Orbimed Advisors LLC holds 7.1M shares of WWB, worth $170.4M.

As of their Nov 16, 2026 Form 4 (filed Nov 18, 2026) · the filing on SEC EDGAR · valued at the Nov 19, 2026 close of $24.01

Orbimed Advisors LLC holds 6.5M shares of ADRX, worth $91.6M, 5.82% of the company.

As of their Sep 28, 2026 Form 4 (filed Sep 30, 2026) · the filing on SEC EDGAR · valued at the Nov 19, 2026 close of $14.16 · 111.2M shares outstanding on Nov 6, 2026 · adjusted for stock splits since

Holdings in 11 more companies are listed under Roles and reported holdings below.

Open-market buys, 24 mo
$109.0M
29 lines
Open-market sales, 24 mo
$103.2M
27 lines
Companies
16
with Form 4 filings
Latest transaction
Nov 16, 2026
transaction date

Roles and reported holdings

  • WWBWINDWARD BIO GROUP AG
    Nov 16, 2026

    Director

    See footnotes7,097,483 sh

    As of Nov 16, 2026 · Form 4

    1 line is priced far from WWB’s market price that day, so the filing may concern a different security. Left out of totals and holdings; see the filings.

  • ETRAElectra Therapeutics, Inc.
    Sep 21, 2026 – Nov 10, 2026

    Director

    See footnotes2,194,579 sh

    As of Nov 6, 2026 · Form 4

    Shares held, direct and indirect, ETRA, after each Form 4
    1.7M2.0M2.2MSep 21, 2026: 1.8M shares (Form 4)Nov 3, 2026: 2.1M shares (Form 4)Nov 6, 2026: 2.2M shares (Form 4)Sep 21, 2026Nov 6, 2026
    FilingShares afterChange
    Nov 6, 20262.2M+58K
    Nov 3, 20262.1M+379K
    Sep 21, 20261.8M—

    24 months: $24.3M bought

  • ASPEAspen Neuroscience, Inc.
    Nov 2, 2026

    Director

    See footnotes3,589,132 sh

    As of Nov 2, 2026 · Form 4

    24 months: $15.0M bought

  • ADRXADARx Pharmaceuticals, Inc.
    Sep 28, 2026

    Director

    See footnotes6,470,585 sh

    As of Sep 28, 2026 · Form 4

    24 months: $16.1M bought

  • BLSMBlossomHill Therapeutics, Inc.
    Aug 10, 2026

    Director

    See footnotes2,714,279 sh

    As of Aug 10, 2026 · Form 4

    24 months: $10.0M bought

  • BRVEBraveheart Bio, Inc.
    Aug 7, 2026

    Director

    See footnotes3,006,663 sh

    As of Aug 7, 2026 · Form 4

    2 lines are priced far from BRVE’s market price that day, so the filing may concern a different security. Left out of totals and holdings; see the filings.

  • SCTXScribe Therapeutics, Inc.
    Jul 27, 2026

    Director

    See footnotes1,348,825 sh

    As of Jul 27, 2026 · Form 4

    24 months: $15.0M bought

  • SIONSionna Therapeutics, Inc.
    Dec 17, 2025 – Jul 7, 2026

    Director

    See footnotes2,469,959 sh

    As of Jul 7, 2026 · Form 4

    Shares held, direct and indirect, SION, after each Form 4
    2.5M2.5M2.6MJun 30, 2026: 2.6M shares (Form 4)Jul 7, 2026: 2.5M shares (Form 4)Jun 30, 2026Jul 7, 2026
    FilingShares afterChange
    Jul 7, 20262.5M−86K
    Jun 30, 20262.6M—

    24 months: $50.9M sold

  • ELVNEnliven Therapeutics, Inc.
    Jun 15, 2026 – Jun 22, 2026

    10% owner

    See Footnotes6,555,102 sh

    As of Jun 22, 2026 · Form 4

    Shares held, direct and indirect, ELVN, after each Form 4
    6.4M6.9M7.5MJun 15, 2026: 7.4M shares (Form 4)Jun 22, 2026: 6.6M shares (Form 4)Jun 15, 2026Jun 22, 2026
    FilingShares afterChange
    Jun 22, 20266.6M−834K
    Jun 15, 20267.4M—

    24 months: $51.7M sold

  • STTKShattuck Labs, Inc.
    Jun 8, 2026 – Jun 11, 2026

    Director

    See Footnote1,051,021 sh

    Also reports 5.3M Pre-Funded Warrants (right to buy), not counted as shares.

    As of Jun 11, 2026 · Form 4

  • QTTBQ32 Bio Inc.
    May 28, 2026

    Director

    Indirect (latest line that moved)625,000 sh

    As of May 28, 2026 · Form 4

    24 months: $15.0M bought

  • PRLDPrelude Therapeutics Inc
    Apr 21, 2026

    Director

    Indirect (latest line that moved)1,126,126 sh

    As of Apr 21, 2026 · Form 4

    24 months: $12.5M bought

  • TRAWTraws Pharma, Inc.
    Apr 16, 2026

    10% owner

    Indirect (latest line that moved)1,793,187 sh

    As of Apr 16, 2026 · Form 4

    24 months: $998K bought

  • IMAImageneBio, Inc.
    Apr 14, 2026

    Director

    Indirect (latest line that moved)384,689 sh

    As of Apr 14, 2026 · Form 4

  • ACETAdicet Bio, Inc.
    Apr 7, 2026 – Apr 8, 2026

    10% owner

    Indirect (latest line that moved)0 sh

    As of Apr 8, 2026 · Form 4

    24 months: $675K sold

  • KROSKeros Therapeutics, Inc.
    Nov 21, 2025

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

How their buys did since

29 open-market purchases against today’s price: +84.1% on average, +106.2% weighted by dollars spent.

DatePaidReturn
Nov 10, 2026ETRA$8.45+5.8%now $8.94
Nov 10, 2026ETRA$8.45+5.8%now $8.94
Nov 9, 2026ETRA$8.24+8.5%now $8.94
Nov 9, 2026ETRA$8.24+8.5%now $8.94
Nov 6, 2026ETRA$7.85+13.9%now $8.94
Nov 6, 2026ETRA$7.85+13.9%now $8.94
Nov 5, 2026ETRA$7.31+22.3%now $8.94
Nov 5, 2026ETRA$7.31+22.3%now $8.94
Nov 4, 2026ETRA$7.07+26.4%now $8.94
Nov 4, 2026ETRA$7.07+26.4%now $8.94
Nov 4, 2026ETRA$7.78+14.9%now $8.94
Nov 4, 2026ETRA$7.78+14.9%now $8.94
Nov 3, 2026ETRA$7.88+13.4%now $8.94
Nov 3, 2026ETRA$7.88+13.4%now $8.94
Nov 3, 2026ETRA$7.84+14.0%now $8.94
Nov 3, 2026ETRA$7.84+14.0%now $8.94
Nov 2, 2026ASPE$15.00-17.4%now $12.39
Sep 28, 2026ADRX$1.55split-adj.+816.2%now $14.16
Sep 28, 2026ADRX$1.55split-adj.+816.2%now $14.16
Sep 28, 2026ADRX$1.55split-adj.+816.2%now $14.16
Sep 21, 2026ETRA$15.00-40.4%now $8.94
Sep 21, 2026ETRA$15.00-40.4%now $8.94
Aug 10, 2026BLSM$16.00-9.9%now $14.41
Jul 27, 2026SCTX$15.00-11.9%now $13.22
May 28, 2026QTTB$8.00+6.0%now $8.48
May 28, 2026QTTB$8.00+6.0%now $8.48
Apr 21, 2026PRLD$4.44-26.8%now $3.25
Apr 21, 2026PRLD$4.44-26.8%now $3.25
Apr 16, 2026TRAW$1.67-86.2%now $0.2300

Each purchase at the price on its Form 4, against the latest trade or close, adjusted for stock splits. Past returns say nothing about future ones.

Transaction history

All 95 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Nov 16, 2026WWBDirectorShares withheld for tax or exercise priceCode F · indirect232$4K@ $17.00Form 4
Nov 16, 2026WWBDirectorOption exerciseCode M · indirect216,668$4K@ $0.0200Form 4
Nov 16, 2026WWBDirectorConversion of derivativeCode C · indirect1,611,008—Form 4
Nov 16, 2026WWBDirectorConversion of derivativeCode C · indirect3,561,936—Form 4
Nov 16, 2026WWBDirectorOpen-market purchaseCode P · indirectPrice far from market; may be another securityAlso reported by Bonita David P1,176,471$20.0M@ $17.00Form 4
Nov 10, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L2,000$17K@ $8.45Form 4
Nov 10, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L20,700$175K@ $8.45Form 4
Nov 9, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L16,000$132K@ $8.24Form 4
Nov 9, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L4,000$33K@ $8.24Form 4
Nov 6, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L39,600$311K@ $7.85Form 4
Nov 6, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L9,816$77K@ $7.85Form 4
Nov 5, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L125,200$915K@ $7.31Form 4
Nov 5, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L30,891$226K@ $7.31Form 4
Nov 4, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L20,000$141K@ $7.07Form 4
Nov 4, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L5,000$35K@ $7.07Form 4
Nov 4, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L37,100$289K@ $7.78Form 4
Nov 4, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L9,267$72K@ $7.78Form 4
Nov 3, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L98,600$777K@ $7.88Form 4
Nov 3, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L24,400$192K@ $7.88Form 4
Nov 3, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L97,800$767K@ $7.84Form 4
Nov 3, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L24,313$191K@ $7.84Form 4
Nov 2, 2026ASPEDirectorOpen-market purchaseCode P · indirectAlso reported by Thompson Peter A.1,000,000$15.0M@ $15.00Form 4
Nov 2, 2026ASPEDirectorConversion of derivativeCode C · indirect507,119—Form 4
Nov 2, 2026ASPEDirectorConversion of derivativeCode C · indirect625,743—Form 4
Nov 2, 2026ASPEDirectorConversion of derivativeCode C · indirect616,984—Form 4
Nov 2, 2026ASPEDirectorConversion of derivativeCode C · indirect642,745—Form 4
Nov 2, 2026ASPEDirectorConversion of derivativeCode C · indirect196,541—Form 4
Sep 28, 2026ADRXDirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L588,235$10.0M@ $17.00Form 4
Sep 28, 2026ADRXDirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L, Chimovits Erez61,516$1.0M@ $17.00Form 4
Sep 28, 2026ADRXDirectorConversion of derivativeCode C · indirect256,448—Form 4
Sep 28, 2026ADRXDirectorConversion of derivativeCode C · indirect513,067—Form 4
Sep 28, 2026ADRXDirectorConversion of derivativeCode C · indirect1,333,975—Form 4
Sep 28, 2026ADRXDirectorConversion of derivativeCode C · indirect7,127,019—Form 4
Sep 28, 2026ADRXDirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L300,249$5.1M@ $17.00Form 4
Sep 28, 2026ADRXDirectorConversion of derivativeCode C · indirect564,187—Form 4
Sep 28, 2026ADRXDirectorConversion of derivativeCode C · indirect769,601—Form 4
Sep 28, 2026ADRXDirectorConversion of derivativeCode C · indirect2,000,962—Form 4
Sep 28, 2026ADRXDirectorConversion of derivativeCode C · indirect10,690,530—Form 4
Sep 21, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L1,000,000$15.0M@ $15.00Form 4
Sep 21, 2026ETRADirectorConversion of derivativeCode C · indirect758,279—Form 4
Sep 21, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L333,333$5.0M@ $15.00Form 4
Sep 21, 2026ETRADirectorConversion of derivativeCode C · indirect1,703,314—Form 4
Sep 21, 2026ETRADirectorConversion of derivativeCode C · indirect1,087,934—Form 4
Sep 21, 2026ETRADirectorConversion of derivativeCode C · indirect2,002,310—Form 4
Aug 10, 2026BLSMDirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L625,000$10.0M@ $16.00Form 4
Aug 10, 2026BLSMDirectorConversion of derivativeCode C · indirect1,049,283—Form 4
Aug 10, 2026BLSMDirectorConversion of derivativeCode C · indirect1,039,996—Form 4
Aug 7, 2026BRVEDirectorConversion of derivativeCode C · indirect40,000,000—Form 4
Aug 7, 2026BRVEDirectorOpen-market purchaseCode P · indirectPrice far from market; may be another securityAlso reported by Chimovits Erez273,333$4.9M@ $18.00Form 4
Aug 7, 2026BRVEDirectorOpen-market purchaseCode P · indirectPrice far from market; may be another securityAlso reported by Chimovits Erez1,666,667$30.0M@ $18.00Form 4
Aug 7, 2026BRVEDirectorConversion of derivativeCode C · indirect9,132,420—Form 4
Jul 27, 2026SCTXDirectorConversion of derivativeCode C · indirect2,065,672—Form 4
Jul 27, 2026SCTXDirectorOpen-market purchaseCode P · indirectAlso reported by GORDON CARL L1,000,000$15.0M@ $15.00Form 4
Jul 27, 2026SCTXDirectorConversion of derivativeCode C · indirect348,825—Form 4
Jul 7, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.85,918$3.9M@ $44.86Form 4
Jun 30, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.115,844$5.3M@ $45.50Form 4
Jun 22, 2026ELVN10% ownerOpen-market saleCode S · indirect46,776$2.1M@ $45.00Form 4
Jun 22, 2026ELVN10% ownerOpen-market saleCode S · indirect787,024$35.7M@ $45.38Form 4
Jun 22, 2026ELVN10% ownerOpen-market saleCode S · indirect1,477$66K@ $45.00Form 4
Jun 22, 2026ELVN10% ownerOpen-market saleCode S · indirect24,846$1.1M@ $45.38Form 4
Jun 15, 2026ELVN10% ownerOpen-market saleCode S · indirect272,322$12.3M@ $45.02Form 4
Jun 15, 2026ELVN10% ownerOpen-market saleCode S · indirect9,086$409K@ $45.02Form 4
Jun 11, 2026STTKDirectorOpen-market purchaseCode P · indirect208,333—Form 4
Jun 11, 2026STTKDirectorOpen-market purchaseCode P · indirect1,041,667—Form 4
Jun 8, 2026STTKDirectorConversion of derivativeCode C · indirect3,073,298—Form 4
Jun 8, 2026STTKDirectorConversion of derivativeCode C · indirect15,366,490—Form 4
May 28, 2026QTTBDirectorOpen-market purchaseCode P · indirectAlso reported by Xu Diyong625,000$5.0M@ $8.00Form 4
May 28, 2026QTTBDirectorOpen-market purchaseCode P · indirectAlso reported by Xu Diyong1,250,000$10.0M@ $8.00Form 4
May 27, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.101$4K@ $44.49Form 4
May 11, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.184,639$8.5M@ $46.22Form 4
May 8, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.59,767$2.7M@ $44.58Form 4
May 7, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.48,546$2.2M@ $44.61Form 4
Apr 21, 2026PRLDDirectorOpen-market purchaseCode P · indirectAlso reported by Bonita David P1,126,126$5.0M@ $4.44Form 4
Apr 21, 2026PRLDDirectorOpen-market purchaseCode P · indirectAlso reported by Bonita David P1,689,189$7.5M@ $4.44Form 4
Apr 18, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.2,948$131K@ $44.52Form 4
Apr 17, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.52,397$2.3M@ $44.68Form 4
Apr 16, 2026TRAW10% ownerOpen-market purchaseCode P · indirect1,793,187—Form 4
Apr 16, 2026TRAW10% ownerOpen-market purchaseCode P · indirect597,729$998K@ $1.67Form 4
Apr 16, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.226,906$10.3M@ $45.34Form 4
Apr 15, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.235,863$10.5M@ $44.64Form 4
Apr 14, 2026IMADirectorOpen-market purchaseCode P · indirect384,689—Form 4
Apr 14, 2026IMADirectorOpen-market purchaseCode P · indirect336,603—Form 4
Apr 14, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.47,814$2.1M@ $44.51Form 4
Apr 8, 2026ACET10% ownerOpen-market saleCode S · indirect40,416$264K@ $6.52Form 4
Apr 8, 2026ACET10% ownerOpen-market saleCode S · indirect32,523$205K@ $6.29Form 4
Apr 7, 2026ACET10% ownerOpen-market saleCode S · indirect2,400$15K@ $6.38Form 4
Apr 7, 2026ACET10% ownerOpen-market saleCode S · indirect29,319$191K@ $6.53Form 4
Feb 3, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.29,063$1.3M@ $44.58Form 4
Feb 2, 2026SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.1,890$84K@ $44.57Form 4
Dec 24, 2025SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.33,356$1.5M@ $44.55Form 4
Dec 19, 2025SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.875$39K@ $44.49Form 4
Dec 18, 2025SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.100$4K@ $44.49Form 4
Dec 17, 2025SIONDirectorOpen-market saleCode S · indirectAlso reported by Thompson Peter A.900$40K@ $44.50Form 4
Nov 21, 2025KROSDirectorDisposition to issuerCode D · indirect74,465$1.3M@ $17.75Form 4
Nov 21, 2025KROSDirectorDisposition to issuerCode D · indirect140,057$2.5M@ $17.75Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares each ownership line is left at by the person’s latest Form 4, 4/A or 5: held directly, and through each trust or entity named on the filing. A second class of common stock that converts into the listed one counts as shares; options and restricted stock units are listed but not counted. Value uses the latest trade or close, and the share of the company uses the latest shares-outstanding count the company reported. Where a filing has not yet been read line by line, the figure comes from the latest direct and indirect lines that traded and is shown as “at least”.

3 open-market lines are priced outside 0.67×–1.5× of the stock’s closing price that day. A gap that large usually means the filing reports a different security than the company it is filed under, so those lines are shown but left out of totals and holdings.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.